Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Johns Hopkins University |
---|---|
Information provided by: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT00311987 |
The natural thyroid hormones, thyroxine (T4) and triiodothyronine (T3), are known to have a cholesterol-lowering effect. Their pharmacologic use for this purpose is limited, however, by their actions on other organs, including the heart, bone, and brain, where there can be side effects of excessive thyroid hormone action. 3,5-diiodothyropropionic acid (DITPA) is a thyroid hormone analog with relative selectivity for a form of the thyroid hormone receptor expressed in the liver, where it regulates several aspects of lipid metabolism, including the clearance of low-density lipoprotein (LDL) cholesterol.
This study is designed to determine whether DITPA is safe and effective in achieving LDL cholesterol levels that are consistent with the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines in patients who have not achieved those levels on conventional therapy, due to drug-resistant disease, drug intolerance, or both.
This is a single-center, randomized, double-blind, placebo-controlled study. Following a 4-week Pre-Randomization Phase with dietary counseling and a 2-week placebo run-in, eligible patients will be randomized (1:1:1) to receive DITPA (90 mg/day, 180 mg/day), or placebo for a total treatment duration of 12 weeks.
Sixty (60) patients will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (i.e., 20 patients per treatment group):
Those patients randomized to receive DITPA at 90 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for 10 weeks.
Those patients randomized to receive DITPA at 180 mg/day will receive 45 mg/day for the first 2 weeks, followed by 90 mg/day for the next 2 weeks, and then 180 mg/day for 8 weeks.
Condition | Intervention | Phase |
---|---|---|
Hypercholesterolemia |
Drug: 3,5-Diiodothyropropionic acid (DITPA) therapy |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind Placebo-Controlled Study of 3,5-Diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients |
Estimated Enrollment: | 60 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | April 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients are eligible for study entry based on the following criteria:
Exclusion Criteria:
Pre-Randomization Exclusion Criteria
Patients will not be eligible for the study based on the following criteria:
Contact: Annabelle Rodriguez, MD | 410-550-4229 | arodrig@jhmi.edu |
United States, Maryland | |
Johns Hopkins Bayview Medical Center | Recruiting |
Baltimore, Maryland, United States, 21224 |
Principal Investigator: | Annabelle Rodriguez, MD | Johns Hopkins University |
Study ID Numbers: | NA_00001376 |
Study First Received: | April 5, 2006 |
Last Updated: | April 13, 2006 |
ClinicalTrials.gov Identifier: | NCT00311987 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hypercholesterolemia Thyroid hormone Diiodothyropropionic acid Therapy |
Metabolic Diseases Hyperlipidemias Hormones Metabolic Disorder |
Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders |
Metabolic Diseases Hyperlipidemias Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders |